Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Lang

Showing results (771-780 of 809) with videos related to

Pageof 81
Sort By:
European Journal of Heart Failure|November 7, 2019
Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targetsThong H Cao, Donald J L Jones, Adriaan A Voors, et al.
European Journal of Heart Failure|December 19, 2017
Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failureJohanna Elisabeth Emmens, Donald J L Jones, Thong H Cao, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 6, 2019
Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillationIfy R Mordi, Bernadet T Santema, Mariëlle Kloosterman, et al.
Lancet (London, England)|August 23, 2011
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trialJohn G F Cleland, John R Teerlink, Roxy Senior, et al.
BMJ Open|May 28, 2025
Clinical effectiveness and cost-effectiveness of the rehabilitation enablement in chronic heart failure facilitated self-care rehabilitation intervention for people with heart failure with preserved ejection fraction and their caregivers: rationale and protocol for a multicentre randomised controlled trial - REACH-HFpEF trialRod S Taylor, Emma Burrell, Claire O'Hare, et al.
European Journal of Heart Failure|January 11, 2020
Genetic risk and atrial fibrillation in patients with heart failureMariëlle Kloosterman, Bernadet T Santema, Carolina Roselli, et al.
Journal of Internal Medicine|May 7, 2020
Tumour biomarkers: association with heart failure outcomesC Shi, H H van der Wal, H H W Silljé, et al.
European Journal of Heart Failure|December 19, 2020
Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHFBeth A Davison, Stefanie Senger, Iziah E Sama, et al.
Journal of Virology|October 13, 2025
Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variantsShilei Ding, Derek Yang, Irfan Ullah, et al.
Trials|April 15, 2022
Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)Seonaidh Cotton, Graham Devereux, Hassan Abbas, et al.
Pageof 81

Showing results (771-780 of 809) with videos related to

Sort By:
Pageof 81
European Journal of Heart Failure|November 7, 2019
Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targetsThong H Cao, Donald J L Jones, Adriaan A Voors, et al.
European Journal of Heart Failure|December 19, 2017
Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failureJohanna Elisabeth Emmens, Donald J L Jones, Thong H Cao, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 6, 2019
Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillationIfy R Mordi, Bernadet T Santema, Mariëlle Kloosterman, et al.
Lancet (London, England)|August 23, 2011
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trialJohn G F Cleland, John R Teerlink, Roxy Senior, et al.
BMJ Open|May 28, 2025
Clinical effectiveness and cost-effectiveness of the rehabilitation enablement in chronic heart failure facilitated self-care rehabilitation intervention for people with heart failure with preserved ejection fraction and their caregivers: rationale and protocol for a multicentre randomised controlled trial - REACH-HFpEF trialRod S Taylor, Emma Burrell, Claire O'Hare, et al.
European Journal of Heart Failure|January 11, 2020
Genetic risk and atrial fibrillation in patients with heart failureMariëlle Kloosterman, Bernadet T Santema, Carolina Roselli, et al.
Journal of Internal Medicine|May 7, 2020
Tumour biomarkers: association with heart failure outcomesC Shi, H H van der Wal, H H W Silljé, et al.
European Journal of Heart Failure|December 19, 2020
Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHFBeth A Davison, Stefanie Senger, Iziah E Sama, et al.
Journal of Virology|October 13, 2025
Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variantsShilei Ding, Derek Yang, Irfan Ullah, et al.
Trials|April 15, 2022
Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)Seonaidh Cotton, Graham Devereux, Hassan Abbas, et al.
Pageof 81